Contravisory Investment Management Inc. Purchases 70,550 Shares of Merck & Co., Inc. $MRK

Contravisory Investment Management Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 19,435.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,913 shares of the company’s stock after purchasing an additional 70,550 shares during the quarter. Contravisory Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $7,464,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. DLD Asset Management LP boosted its position in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at $2,858,570,000. Fisher Asset Management LLC increased its position in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Fisher Asset Management LLC now owns 25,013,697 shares of the company’s stock valued at $1,980,084,000 after buying an additional 567,900 shares in the last quarter. Legal & General Group Plc raised its stake in Merck & Co., Inc. by 5.9% during the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock worth $1,733,923,000 after buying an additional 1,156,112 shares during the period. Finally, Invesco Ltd. raised its stake in Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after buying an additional 2,821,766 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

MRK opened at $115.65 on Tuesday. The business’s 50-day moving average price is $115.94 and its two-hundred day moving average price is $101.09. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a market capitalization of $285.93 billion, a price-to-earnings ratio of 15.89, a P/E/G ratio of 2.21 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insider Activity

In other news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This trade represents a 63.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Bank of America boosted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. The Goldman Sachs Group lifted their price objective on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald increased their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. Finally, BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $127.13.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.